Literature DB >> 33428127

Advances in Drug Therapy for Alzheimer's Disease.

Chuan-Cong Zhu1, Si-Yu Fu1, Yu-Xin Chen1, Ling Li1, Ruo-Lin Mao1, Jian-Zhi Wang1,2, Rong Liu1, Yi Liu3, Xiao-Chuan Wang4,5.   

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disease that mainly causes dementia. It is a serious threat to the health of the global elderly population. Considerable money and effort has been invested in the development of drug therapy for AD worldwide. Many drug therapies are currently under development or in clinical trials, based on two known mechanisms of AD, namely, Aβ toxicity and the abnormal Tau hyperphosphorylation. Numerous drugs are also being developed for other AD associated mechanisms such as neuroinflammation, neurotransmitter imbalance, oxidative damage and mitochondrial dysfunction, neuron loss and degeneration. Even so, the number of drugs that can successfully improve symptoms or delay the progression of the disease remains very limited. However, multi-drug combinations may provide a new avenue for drug therapy for AD. In addition, early diagnosis of AD and timely initiation of treatment may allow drugs that act on the early pathological processes of AD to help improve the symptoms and prevent the progression of the condition.

Entities:  

Keywords:  Alzheimer’s disease; Aβ; drug therapy; tau

Year:  2021        PMID: 33428127     DOI: 10.1007/s11596-020-2281-2

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  56 in total

Review 1.  Neuropathologic changes in Alzheimer's disease.

Authors:  Gary L Wenk
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

Review 2.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

Review 3.  The role of A beta 42 in Alzheimer's disease.

Authors:  S G Younkin
Journal:  J Physiol Paris       Date:  1998 Jun-Aug

Review 4.  Alzheimer's disease.

Authors:  C A Lane; J Hardy; J M Schott
Journal:  Eur J Neurol       Date:  2017-10-19       Impact factor: 6.089

5.  Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Authors:  Robert Howard; Rupert McShane; James Lindesay; Craig Ritchie; Ashley Baldwin; Robert Barber; Alistair Burns; Tom Dening; David Findlay; Clive Holmes; Alan Hughes; Robin Jacoby; Rob Jones; Roy Jones; Ian McKeith; Ajay Macharouthu; John O'Brien; Peter Passmore; Bart Sheehan; Edmund Juszczak; Cornelius Katona; Robert Hills; Martin Knapp; Clive Ballard; Richard Brown; Sube Banerjee; Caroline Onions; Mary Griffin; Jessica Adams; Richard Gray; Tony Johnson; Peter Bentham; Patrick Phillips
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

6.  Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity.

Authors:  Xiao-Ping Shi; Katherine Tugusheva; James E Bruce; Adam Lucka; Guo-Xin Wu; Elizabeth Chen-Dodson; Eric Price; Yueming Li; Min Xu; Qian Huang; Mohinder K Sardana; Daria J Hazuda
Journal:  J Biol Chem       Date:  2003-03-27       Impact factor: 5.157

Review 7.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

8.  A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease.

Authors:  Erik Portelius; Robert A Dean; Mikael K Gustavsson; Ulf Andreasson; Henrik Zetterberg; Eric Siemers; Kaj Blennow
Journal:  Alzheimers Res Ther       Date:  2010-03-29       Impact factor: 6.982

Review 9.  Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.

Authors:  Christopher Hyde; Jaime Peters; Mary Bond; Gabriel Rogers; Martin Hoyle; Rob Anderson; Mike Jeffreys; Sarah Davis; Praveen Thokala; Tiffany Moxham
Journal:  Age Ageing       Date:  2012-11-22       Impact factor: 10.668

10.  The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Authors:  Ulf Neumann; Mike Ufer; Laura H Jacobson; Marie-Laure Rouzade-Dominguez; Gunilla Huledal; Carine Kolly; Rainer M Lüönd; Rainer Machauer; Siem J Veenstra; Konstanze Hurth; Heinrich Rueeger; Marina Tintelnot-Blomley; Matthias Staufenbiel; Derya R Shimshek; Ludovic Perrot; Wilfried Frieauff; Valerie Dubost; Hilmar Schiller; Barbara Vogg; Karen Beltz; Alexandre Avrameas; Sandrine Kretz; Nicole Pezous; Jean-Michel Rondeau; Nicolau Beckmann; Andreas Hartmann; Stefan Vormfelde; Olivier J David; Bruno Galli; Rita Ramos; Ana Graf; Cristina Lopez Lopez
Journal:  EMBO Mol Med       Date:  2018-11       Impact factor: 12.137

View more
  2 in total

Review 1.  Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease.

Authors:  Klaus Grossmann
Journal:  Biomedicines       Date:  2022-08-04

2.  Effects of Tai Chi Softball Exercises on Physical Fitness Level and Cardiovascular Health-Related Factors among Older Females.

Authors:  XiaoDong Cheng; Yongzhao Fan; Ling Ge; Desen Zang; Jianxi Li; Jian Li; Hao Wu
Journal:  J Healthc Eng       Date:  2021-07-02       Impact factor: 2.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.